Showing results (71-80 of 160) with videos related to
Sort By:
Pageof 16
European Journal of Nuclear Medicine and Molecular Imaging|November 2, 2021
Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand therapyFlorian Rosar, Felix Wenner, Fadi Khreish, et al.Cancers|April 12, 2022
Upregulation of PSMA Expression by Enzalutamide in Patients with Advanced mCRPCFlorian Rosar, Robert Neher, Caroline Burgard, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 28, 2010
The significance of 99mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for 90Y-microsphere selective internal radiation treatmentHojjat Ahmadzadehfar, Amir Sabet, Kim Biermann, et al.European Journal of Nuclear Medicine and Molecular Imaging|August 18, 2016
Distinguishing synchronous from metachronous manifestation of distant metastases: a prognostic feature in differentiated thyroid carcinomaAmir Sabet, Ina Binse, Semih Dogan, et al.European Journal of Nuclear Medicine and Molecular Imaging|April 28, 2016
Prognostic impact of incomplete surgical clearance of radioiodine sensitive local lymph node metastases diagnosed by post-operative (124)I-NaI-PET/CT in patients with papillary thyroid cancerAmir Sabet, Ina Binse, Hong Grafe, et al.European Journal of Nuclear Medicine and Molecular Imaging|October 27, 2023
Change in total lesion PSMA (TLP) during [177Lu]Lu-PSMA-617 radioligand therapy predicts overall survival in patients with mCRPC: monocentric evaluation of a prospective registryCaroline Burgard, Connor Hein, Arne Blickle, et al.American Journal of Nuclear Medicine and Molecular Imaging|May 24, 2017
Efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in metastatic pulmonary neuroendocrine tumors: a dual-centre analysisAmir Sabet, Alexander R Haug, Collin Eiden, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 9, 2013
Long-term outcome and toxicity after dose-intensified treatment with 131I-MIBG for advanced metastatic carcinoid tumorsSamer Ezziddin, Amir Sabet, Timur Logvinski, et al.Frontiers in Medicine|February 1, 2024
Change of glucometabolic activity per PSMA expression predicts survival in mCRPC patients non-responding to PSMA radioligand therapy: introducing a novel dual imaging biomarkerCaroline Burgard, Jakob Engler, Arne Blickle, et al.European Journal of Nuclear Medicine and Molecular Imaging|February 8, 2014
Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumoursSamer Ezziddin, Feras Khalaf, Maria Vanezi, et al.Pageof 16